OTO-313
Drug
Otonomy, Inc.
Total Payments
$513,049
Transactions
46
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $513,049 | 46 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $512,549 | 45 | 99.9% |
| Consulting Fee | $500.00 | 1 | 0.1% |
Payments by Type
Research
$512,549
45 transactions
General
$500.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus | Otonomy, Inc. | $512,549 | 1 |
Ad
Manufacturing Companies
- Otonomy, Inc. $513,049
Product Information
- Type Drug
- Total Payments $513,049
- Total Doctors 2
- Transactions 46
About OTO-313
OTO-313 is a drug associated with $513,049 in payments to 2 healthcare providers, recorded across 46 transactions in the CMS Open Payments database. The primary manufacturer is Otonomy, Inc..
Payment data is available from 2020 to 2020. In 2020, $513,049 was paid across 46 transactions to 2 doctors.
The most common payment nature for OTO-313 is "Unspecified" ($512,549, 99.9% of total).
OTO-313 is associated with 1 research study, including "A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus" ($512,549).